Summary

Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

Market Overview

During the forecast period, the Biodefense Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.01%.
In preparation for potential bioterrorism attacks, governments are allocating substantial resources to vaccine research and development. Pharmaceutical companies that operate in the biodefense market have been presented with substantial opportunities to expand as a result of government initiatives to prepare for any form of bioterrorism. Additionally, governments worldwide are implementing initiatives to improve their biodefense capabilities. The biodefense market is experiencing growth because of increased funding for research and development, preparedness planning, infrastructure development, and the procurement of vaccines and medications.

Market segment insights
Anthrax, smallpox, botulism, influenza, radiation/nuclear, and other diseases comprise the Biodefense Market segmentation organized by disease type.
The segmentation of the Biodefense Market is based on the treatment, which includes vaccination and medication.

Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Biodefense market held the greatest market share. This is a result of the increasing prevalence of infectious diseases in the region, including HIV, viral hepatitis, and influenza. For example, the Centers for Disease Control and Prevention (CDC) estimated that approximately 9 million individuals in the United States were diagnosed with the influenza virus in 2021. This trend is anticipated to continue as antimicrobial resistance continues to increase. Furthermore, the market is anticipated to be driven by the increasing demand for affordable diagnostic tests, vaccines, and therapeutics to combat these infectious diseases.

The second-largest market share in the Europe Biodefense market is attributed to the increasing prevalence of chronic diseases and the increase in research and development activities for biodefense solutions throughout the region. Additionally, the German biodefense market was identified as having the greatest market share, while the Rest of Europe biodefense market is anticipated to be the fastest-growing market in the European region.

It is anticipated that the Asia-Pacific Biodefense market will experience substantial growth from 2023 to 2030. The primary factor fueling the market's growth is the rise in the prevalence of the patient population throughout the region. The region's consumers are facing a significant health risk due to the widespread epidemics of infectious diseases, including influenza and Covid-19, as well as the rise in the number of reported infections of communicable diseases. Moreover, the Japan Biodefense market is anticipated to have the highest market share, while the Rest of Asia-Pacific Biodefense market is anticipated to be the fastest-growing market in the Asia-Pacific region.

The Middle East, Africa, and Latin America comprise the Rest of the World. An increase in the prevalence of infectious diseases, including influenza and Covid-19, is expected to drive growth in the biodefense market in the regions.

Major Players
Emergent (US), Novavax, Inc. (US), Fabentech Biotech (France), SIGA Technologies (US), Dynavax Technologies (US), Altimmune (US), Bavarian Nordic (Denmark), Elusys Therapeutics, Inc. (US), Cleveland Biolabs, Inc. (US), and Ology Bioservices (US) are among the key companies in the Biodefense Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING GOVERNMENT INITIATIVES AND FUNDING
4.2.2 RISE IN DEMAND FOR VACCINES
4.3 RESTRAINTS
4.3.1 LOW MARKET PENETRATION IN DEVELOPING AND UNDERDEVELOPED COUNTRIES
4.4 OPPORTUNITIES
4.4.1 TECHNOLOGICAL ADVANCEMENT
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL BIODEFENSE MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON REGIONS
5.3.4 IMPACT ON PRICING
5.4 AUTHORITIES BUDGET AND FINANCING PROGRAMS FOR BIODEFENSE BY REGION
6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 ANTHRAX
6.3 SMALL POX
6.4 BOTULISM
6.5 INFLUENZA
6.6 RADIATION/NUCLEAR
6.7 OTHERS
7 GLOBAL BIODEFENSE MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 VACCINATION
7.3 MEDICATION
8 GLOBAL BIODEFENSE MARKET, BY REGION
8.1 GLOBAL OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 INDIA
8.4.3 SOUTH KOREA
8.4.4 AUSTRALIA
8.4.5 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN GLOBAL BIODEFENSE MARKET
9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BIODEFENSE MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
9.6.2 PARTNERSHIP/COLLABORATION/AGREEMENT
9.6.3 ACQUISITION/EXPANSION/INVESTMENT
9.7 MAJOR PLAYERS FINANCIAL
9.7.1 SALES, 2023
9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2023
10 COMPANY PROFILE
10.1 EMERGENT
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 BAVARIAN NORDIC
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 ALTIMMUNE
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 DYNAVAX TECHNOLOGIES
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 SIGA TECHNOLOGIES
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 ELUSYS THERAPEUTICS, INC.
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIES
10.7 FABENTECH BIOTECH
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 CLEVELAND BIOLABS, INC.
10.8.1 COMPANY OVERVIEWS
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 OLOGY BIOSERVICES, INC.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 NOVAVAX, INC.
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS